SAVA — Cassava Sciences Inc
NASDAQ · Healthcare · Biotechnology
Cassava Sciences Inc (SAVA) is a biotechnology company listed on NASDAQ. It is led by Richard Jon Barry, based in 6801 N. Capital of Texas Highway, Austin, TX, United States, 78731, with about 30 employees. Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The company was incorporated in 1998 and is based in Austin, Texas.
Net income was -$10.8M. SAVA currently screens at market cap $115.0M.
Use this SAVA page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the SAVA quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the SAVA SEC filings page. Lician reads the product cache first so this HTML stays unique to Cassava Sciences Inc even when a live quote feed is slow.
About Cassava Sciences Inc
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The company was incorporated in 1998 and is based in Austin, Texas.
SAVA Key Statistics
Market Cap
$114.97M
P/B Ratio
0.92
EPS
-$1.46
Revenue
$0.00
Net Income
-$24.34M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
30
SAVA Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$24.34M | -$97.22M | -$76.25M | -$32.38M |
| EPS (Diluted) | -$1.46 | -$2.32 | -$1.90 | $0.00 |
Total Assets
$157.53M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$128.57M
Operating Cash Flow
-$116.93M
Free Cash Flow
$0.00
Cassava Sciences Inc Company Information
- CEO, President & Director
- Richard Jon Barry
- Headquarters
- 6801 N. Capital of Texas Highway, Austin, TX, United States, 78731
- Website
- www.cassavasciences.com
- Phone
- 512 501 2444
- IPO / Founded
- 2000-07-14
- Sector
- Healthcare
- Industry
- Biotechnology